FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1502430008> ?p ?o ?g. }

• W1502430008 abstract "Background Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an update of a Cochrane review first published in 2004, and previously updated (conclusions not changed) in 2007. Objectives To describe and assess the evidence from controlled trials on the efficacy and tolerability of valproate (valproic acid or sodium valproate or a combination of the two) for preventing migraine attacks in adult patients with episodic migraine. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library 2012, Issue 12), PubMed/MEDLINE (1966 to 15 January 2013), MEDLINE In‐Process (current week, 15 January 2013), and EMBASE (1974 to 15 January 2013) and handsearched Headache and Cephalalgia through January 2013. Selection criteria Studies were required to be prospective, controlled trials of valproate taken regularly to prevent the occurrence of migraine attacks, to improve migraine‐related quality of life, or both. Data collection and analysis Two review authors independently selected studies and extracted data. For headache frequency data, we calculated mean differences (MDs) between valproate and comparator (placebo, active control, or valproate in a different dose) for individual studies and pooled these across studies. For dichotomous data on responders (patients with ≥ 50% reduction in headache frequency), we calculated odds ratios (ORs) and, in select cases, risk ratios (RRs); we also calculated numbers needed to treat (NNTs). We calculated MDs for Migraine Disability Assessment (MIDAS) scores. We also summarised data on adverse events from placebo‐controlled trials and calculated risk differences (RDs) and numbers needed to harm (NNHs). Main results Ten papers describing 10 unique trials met the inclusion criteria. Analysis of data from two trials (63 participants) showed that sodium valproate reduced headache frequency by approximately four headaches per 28 days as compared to placebo (MD ‐4.31; 95% confidence interval (CI) ‐8.32 to ‐0.30). Data from four trials (542 participants) showed that divalproex sodium (a stable combination of sodium valproate and valproic acid in a 1:1 molar ratio) more than doubled the proportion of responders relative to placebo (RR 2.18; 95% CI 1.28 to 3.72; NNT 4; 95% CI 2 to 11). One study of sodium valproate (34 participants) versus placebo supported the latter findings (RR for responders 2.83; 95% CI 1.27 to 6.31; NNT 3; 95% CI 2 to 9). There was no significant difference in the proportion of responders between sodium valproate versus flunarizine (one trial, 41 participants) or between divalproex sodium versus propranolol (one trial, 32 participants). Pooled analysis of post‐treatment mean headache frequencies in two trials (88 participants) demonstrates a slight but significant advantage for topiramate 50 mg over valproate 400 mg (MD ‐0.90; 95% CI ‐1.58 to ‐0.22). For placebo‐controlled trials of sodium valproate and divalproex sodium, NNHs for clinically important adverse events ranged from 7 to 14. Authors' conclusions Valproate is effective in reducing headache frequency and is reasonably well tolerated in adult patients with episodic migraine." @default.
• W1502430008 created "2016-06-24" @default.
• W1502430008 creator A5016685655 @default.
• W1502430008 creator A5048551954 @default.
• W1502430008 creator A5058330744 @default.
• W1502430008 creator A5062942636 @default.
• W1502430008 date "2013-06-24" @default.
• W1502430008 modified "2023-10-01" @default.
• W1502430008 title "Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults" @default.
• W1502430008 cites W102427047 @default.
• W1502430008 cites W1480729244 @default.
• W1502430008 cites W1496145302 @default.
• W1502430008 cites W1502430008 @default.
• W1502430008 cites W1507326941 @default.
• W1502430008 cites W1510585453 @default.
• W1502430008 cites W1674600634 @default.
• W1502430008 cites W1747160123 @default.
• W1502430008 cites W1793427412 @default.
• W1502430008 cites W1829545883 @default.
• W1502430008 cites W1842552614 @default.
• W1502430008 cites W186677802 @default.
• W1502430008 cites W1963569078 @default.
• W1502430008 cites W1970386351 @default.
• W1502430008 cites W1980882517 @default.
• W1502430008 cites W1983510560 @default.
• W1502430008 cites W1985839131 @default.
• W1502430008 cites W1986215651 @default.
• W1502430008 cites W1987960446 @default.
• W1502430008 cites W1999079579 @default.
• W1502430008 cites W2005019244 @default.
• W1502430008 cites W2008052893 @default.
• W1502430008 cites W2017549423 @default.
• W1502430008 cites W2033804880 @default.
• W1502430008 cites W2036913626 @default.
• W1502430008 cites W2038693293 @default.
• W1502430008 cites W2047159218 @default.
• W1502430008 cites W205809617 @default.
• W1502430008 cites W2059981326 @default.
• W1502430008 cites W2064887066 @default.
• W1502430008 cites W2066289781 @default.
• W1502430008 cites W2073738656 @default.
• W1502430008 cites W2074813714 @default.
• W1502430008 cites W2077219114 @default.
• W1502430008 cites W2078402149 @default.
• W1502430008 cites W2084808219 @default.
• W1502430008 cites W2097658817 @default.
• W1502430008 cites W2103674233 @default.
• W1502430008 cites W2108344016 @default.
• W1502430008 cites W2109212419 @default.
• W1502430008 cites W2113941122 @default.
• W1502430008 cites W2118951341 @default.
• W1502430008 cites W2123978981 @default.
• W1502430008 cites W2125350651 @default.
• W1502430008 cites W2135255451 @default.
• W1502430008 cites W2136324281 @default.
• W1502430008 cites W2147394426 @default.
• W1502430008 cites W2149500018 @default.
• W1502430008 cites W2160202859 @default.
• W1502430008 cites W2322761953 @default.
• W1502430008 cites W2463097706 @default.
• W1502430008 cites W2586999644 @default.
• W1502430008 cites W2906486020 @default.
• W1502430008 cites W32584114 @default.
• W1502430008 cites W4247292047 @default.
• W1502430008 cites W429368407 @default.
• W1502430008 cites W4298184796 @default.
• W1502430008 doi "https://doi.org/10.1002/14651858.cd010611" @default.
• W1502430008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23797677" @default.
• W1502430008 hasPublicationYear "2013" @default.
• W1502430008 type Work @default.
• W1502430008 sameAs 1502430008 @default.
• W1502430008 citedByCount "98" @default.
• W1502430008 countsByYear W15024300082013 @default.
• W1502430008 countsByYear W15024300082014 @default.
• W1502430008 countsByYear W15024300082015 @default.
• W1502430008 countsByYear W15024300082016 @default.
• W1502430008 countsByYear W15024300082017 @default.
• W1502430008 countsByYear W15024300082018 @default.
• W1502430008 countsByYear W15024300082019 @default.
• W1502430008 countsByYear W15024300082020 @default.
• W1502430008 countsByYear W15024300082021 @default.
• W1502430008 countsByYear W15024300082022 @default.
• W1502430008 countsByYear W15024300082023 @default.
• W1502430008 crossrefType "journal-article" @default.
• W1502430008 hasAuthorship W1502430008A5016685655 @default.
• W1502430008 hasAuthorship W1502430008A5048551954 @default.
• W1502430008 hasAuthorship W1502430008A5058330744 @default.
• W1502430008 hasAuthorship W1502430008A5062942636 @default.
• W1502430008 hasConcept C118552586 @default.
• W1502430008 hasConcept C126322002 @default.
• W1502430008 hasConcept C142724271 @default.
• W1502430008 hasConcept C156957248 @default.
• W1502430008 hasConcept C168563851 @default.
• W1502430008 hasConcept C17744445 @default.
• W1502430008 hasConcept C187212893 @default.
• W1502430008 hasConcept C197934379 @default.
• W1502430008 hasConcept C199539241 @default.
• W1502430008 hasConcept C204787440 @default.
• W1502430008 hasConcept C27081682 @default.
• W1502430008 hasConcept C2776478404 @default.

• next